Illumina Inc. (NASDAQ:ILMN) was downgraded by equities researchers at Vetr from a “buy” rating to a “sell” rating in a research note issued to investors on Tuesday. They presently have a $142.96 price objective on the life sciences company’s stock. Vetr‘s target price would suggest a potential downside of 4.76% from the stock’s current price.
Illumina (NASDAQ:ILMN) traded down 0.36% on Tuesday, hitting $150.10. The company had a trading volume of 1,656,494 shares. Illumina has a 12-month low of $127.10 and a 12-month high of $220.86. The stock has a market cap of $22.09 billion and a P/E ratio of 53.97. The firm’s 50 day moving average price is $142.93 and its 200 day moving average price is $149.99.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.13. During the same period last year, the firm earned $0.80 earnings per share. The firm had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. Illumina’s revenue for the quarter was up 11.3% compared to the same quarter last year. Equities analysts predict that Illumina will post $3.37 earnings per share for the current fiscal year.
In other news, EVP Christian O. Henry sold 2,141 shares of the firm’s stock in a transaction that occurred on Wednesday, April 27th. The shares were sold at an average price of $138.46, for a total transaction of $296,442.86. Following the completion of the sale, the executive vice president now owns 27,073 shares of the company’s stock, valued at $3,748,527.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert S. Epstein sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $150.00, for a total transaction of $180,000.00. Following the sale, the director now directly owns 7,824 shares of the company’s stock, valued at approximately $1,173,600. The disclosure for this sale can be found here.
Several other brokerages also recently issued reports on ILMN. Bank of America Corp. downgraded shares of Illumina from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 19th. Cowen and Company reaffirmed an “outperform” rating and issued a $180.00 price target (down from $215.00) on shares of Illumina in a research note on Tuesday, April 19th. BTIG Research reaffirmed a “hold” rating on shares of Illumina in a research note on Tuesday, April 19th. Leerink Swann reaffirmed a “market perform” rating and issued a $165.00 price target (down from $175.00) on shares of Illumina in a research note on Tuesday, April 19th. Finally, Cantor Fitzgerald downgraded shares of Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $225.00 to $165.00 in a research note on Tuesday, April 19th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $164.69.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
